Effect of Novartis Access on availability and price of non-communicable disease medicines in Kenya: A cluster-randomised controlled trial
Loading...
Date
2019
Journal Title
Journal ISSN
Volume Title
Publisher
Elsevier
Abstract
Novartis Access is a Novartis programme that offers a portfolio of non-communicable disease medicines at a wholesale price of US$1 per treatment per month in low-income and middle-income countries. We evaluated the effect of Novartis Access in Kenya, the first country to receive the programme.Methods We did a cluster-randomised controlled trial in eight counties in Kenya. Counties (clusters) were randomly assigned to the intervention or the control group with a covariate-constrained randomisation procedure that maximised balance on a set of demographic and health variables. In intervention counties, public and non-profit health facilities were allowed to purchase Novartis Access medicines from the Mission for Essential Drugs and Supplies (MEDS). Data were collected from all facilities served by MEDS and a sample of households in study counties. Households were eligible if they had at least one adult patient who had been diagnosed and prescribed medicines for one of the non-communicable diseases targeted by the programme: hypertension, heart failure, dyslipidaemia, type 2 diabetes, asthma, or breast cancer. Primary outcomes were availability and price of portfolio medicines at health facilities, irrespective of brand; and availability of medicines at patient households. Impacts were estimated with intention-to-treat analysis. This trial is registered with ClinicalTrials.gov (NCT02773095).
Description
Keywords
Non-communicable diseases, Kenya, Medicines use
Citation
Rockers et al. (2019). Effect of Novartis Access on availability and price of non-communicable disease medicines in Kenya: A cluster-randomised controlled trial. The Lancet Global Health, 7(4), e492–e502. https://doi.org/10.1016/S2214-109X(18)30563-1